Please try another search
For the nine months ended 30 September 2020, PrevailTherapeutics Inc revenues was not reported. Net lossincreased 31% to $59.3M. Higher net loss reflects Generaland administrative - Balan increase from $8.8M to $20M(expense), Stock-Based Compensation in General and increasefrom $1.3M to $3.3M (expense), Interest income decrease of69% to $582K (income). Basic Earnings per Share excludingExtraordinary Items decreased from -$1.33 to -$1.77.
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -18.62 | -22.15 | -19.28 | -18.55 |
Net Income | -18.59 | -22.1 | -18.57 | -17.84 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 134.12 | 150.69 | 168.8 | 187.1 |
Total Liabilities | 21.54 | 22.04 | 20.34 | 21.76 |
Total Equity | 112.58 | 128.66 | 148.46 | 165.34 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -53.23 | -36.59 | -18.25 | -55.75 |
Cash From Investing Activities | -33.22 | -20.5 | -0.29 | -2.14 |
Cash From Financing Activities | 0.14 | 0.11 | 0.06 | 162.93 |
Net Change in Cash | -86.32 | -56.99 | -18.47 | 105.04 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review